More patients from fewer sites in less time.

SynexusPlus combines AES’s global site network services with supercharged patient recruitment capabilities to provide a competitive strategy for trial enrollment. Through proprietary feasibility and high enrolling global sites, SynexusPlus delivers up to 80% of the patients you need, in less time and from a more efficient site footprint. This combined solution is best suited for clinical trial sponsors or CROs who are in the trial planning phase and have not yet determined their strategy for sites and countries.

Optimal Vaccine Centers of Excellence (OVCoE) supercharges the world’s largest vaccine site network with accelerated patient enrollment, advanced lab capabilities, and specialized vaccine services – all delivered under a results-based contracting model for total budget certainty. With OVCoE, the leading global site network (Synexus) and leading vaccine specialists (Optimal) combine to optimize productivity and efficiency for vaccine clinical trials.

PatientAdvantage is a comprehensive, accelerated clinical trial strategy, based on a patients-first approach. This combined solution includes patient enrollment, global sites, and core CRO services, and delivers up to 100% of the patients needed. The results are unparalleled speed and budget certainty, including fixed price contracts that cover both direct and indirect fees at a price per patient. PatientAdvantage, for sponsors who fully outsource, should be engaged in the trial planning phase to maximize the benefits of this combined solution.

Synexus is the world’s leading site network for clinical trials, offering unmatched capabilities to help biopharmaceutical and CRO customers find the right patient for the right trial at the right time. The Synexus global site network includes nearly 200 clinical research facilities, providing data-driven site selection and activation expertise across the U.S., Europe, Africa, and India.

Acurian is the leading full-service patient enrollment and retention solution, offering a patient-centric approach to increase the enrollment performance of trial sites. Site enrollment rates increase by an average of 50% using this approach that rapidly sources, pre-screens, and delivers high-quality patients who live near – but are unknown to – clinical research sites. Fully identified data is at the heart of the solution and includes more than 100 million households with one or more opted-in patients, and more than 20 million patients who have already pre-screened across thousands of previous clinical trials.

Optimal Just-in-Time (JIT) jumpstarts oncology trial enrollment and delivers the first patient faster, then continues to find patients to accelerate overall timelines. The Optimal JIT solution includes a community of 300 oncology research sites, all pre-contracted, pre-qualified, and ready for rapid activation into a trial. This solution methodology means no site is initiated or paid until it has pre-identified an eligible patient and is approved by the sponsor. On approval, it takes only two weeks to activate the site and offer the study to the patient. The result is cancer patients get the treatment they need, in the community where they live, from the physicians they trust, surrounded by the people they love.